최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기International congress series, v.1244, 2002년, pp.11 - 20
Bertilsson, Leif (Tel.: +46-8-585-810-71)
AbstractIn 1980, we published two papers of importance for the future of our research: (i) it was shown that the two polymorphic hydroxylations of debrisoquine and sparteine are catalysed by a common enzyme now called CYP2D6 and (ii) that this polymorphic enzyme also catalysed the metabolism of the ...
Life Sci. Hammer 6 1895 1967 10.1016/0024-3205(67)90218-4 Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds
Br. Med. J. Alexanderson 4 764 1969 10.1136/bmj.4.5686.764 Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy
Life Sci. Bertilsson 27 1673 1980 10.1016/0024-3205(80)90642-6 Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man
Bertilsson 15 2001 Interindividual Variability in Drug Metabolism in Humans Interethnic differences is drug disposition and effects
Trends Pharmacol. Sci. Ingelman-Sundberg 20 324 1999 10.1016/S0165-6147(99)01363-2 Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
Br. J. Clin. Pharmacol. Bertilsson 53 111 2002 10.1046/j.0306-5251.2001.01548.x Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Lancet Mahgoub 2 584 1977 10.1016/S0140-6736(77)91430-1 Polymorphic hydroxylation of debrisoquine in man
Lancet Tucker 2 718 1977 10.1016/S0140-6736(77)90527-X Polymorphic hydroxylation of debrisoquine in man
Eur. J. Clin. Pharmacol. Eichelbaum 16 183 1979 10.1007/BF00562059 Defective N-oxidation of sparteine in man: a new pharmacogenetic defect
Clin. Pharmacol. Ther. Eichelbaum 31 184 1982 10.1038/clpt.1982.29 Polymorphic oxidation of sparteine and debrisoquine. Related pharmacogenetic entities
Eur. J. Clin. Pharmacol. Alvan 39 533 1990 10.1007/BF00316090 Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
Clin. Pharmacol. Ther. Bertilsson 51 388 1992 10.1038/clpt.1992.38 Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin
Br. J. Clin. Pharmacol. Sohn 32 504 1991 10.1111/j.1365-2125.1991.tb03939.x Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations
Clin. Pharmacol. Ther. Dahl 51 12 1992 10.1038/clpt.1992.2 Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population
Mol. Pharmacol. Johansson 46 452 1994 Genetic analysis of the Chinese CYP2D locus. Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
Br. J. Clin. Pharmacol. Masimirembwa 42 713 1996 10.1046/j.1365-2125.1996.00489.x A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity
Proc. Natl. Acad. Sci. U. S. A. Johansson 90 11825 1993 10.1073/pnas.90.24.11825 Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine
Ther. Drug Monit. Bertilsson 7 478 1985 10.1097/00007691-198512000-00021 Extremely rapid hydroxylation of debrisoquine-a case report with implication for treatment with nortriptyline and other tricyclic antidepressants
Lancet Bertilsson 341 63 1993 10.1016/0140-6736(93)92546-6 Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
J. Pharmacol. Exp. Ther. Dahl 274 516 1995 Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
Pharmacogenetics Bernal 9 657 1999 10.1097/00008571-199910000-00013 Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
Clin. Pharmacol. Ther. Agundez 57 265 1995 10.1016/0009-9236(95)90151-5 Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population
Psychopharmacology Scordo 147 300 1999 10.1007/s002130051171 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxy risperidone
J. Pharmacol. Exp. Ther. Aklillu 278 441 1996 Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
Pharmacogenetics Nishida 10 567 2000 10.1097/00008571-200008000-00010 CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D*10
Clin. Pharmacol. Ther. Mellstrom 30 189 1981 10.1038/clpt.1981.147 E- and Z-hydroxylation of nortriptyline in man - relationship to polymorphic hydroxylation of debrisoquine
Clin. Pharmacol. Ther. Dalen 63 444 1998 10.1016/S0009-9236(98)90040-6 10-Hydroxylation of nortriptyline in Caucasians with 0, 1, 2, 3 and 13 functional CYP2D6 genes
Psychopharmacology Dahl 123 315 1996 10.1007/BF02246640 Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype
J. Clin. Psychopharmacol. Morita 20 141 2000 10.1097/00004714-200004000-00005 Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline
Lancet Bertilsson 1 560 1982 Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implication
Sjoqvist 359 1984 Frontiers in Biochemical and Pharmacological Research in Depression Clinical pharmacology of antidepressant drugs: pharmacogenetics
Ther. Drug Monit. Llerena 14 92 1992 10.1097/00007691-199204000-00003 Haloperidol disposition is dependent of debrisoquine hydroxylation phenotype
Am. J. Psychiatry Nyberg 152 173 1995 10.1176/ajp.152.2.173 D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate
Pharmacogenetics Suzuki 7 415 1997 10.1097/00008571-199710000-00013 Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients
Clin. Pharmacol. Ther. Mihara 65 291 1999 10.1016/S0009-9236(99)70108-6 Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
Br. J. Clin. Pharmacol. Roh 52 265 2001 10.1046/j.0306-5251.2001.01437.x Plasma concentrations of haloperidol are related to the CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
Pharmacogenetics Griese 8 15 1998 10.1097/00008571-199802000-00003 Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
Pharmacogenetics Raimundo 10 577 2000 10.1097/00008571-200010000-00001 Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.